References
- Kopecka J, Campia I, Olivero P, Pescarmona G, Ghigo D, Bosia A, et al. A LDL-masked liposomal-doxorubicin reverses drug resistance in human cancer cells. J Control Release 2011; 149:196 - 205; http://dx.doi.org/10.1016/j.jconrel.2010.10.003; PMID: 20946921
- Riganti C, Orecchia S, Pescarmona G, Betta PG, Ghigo D, Bosia A. Statins revert doxorubicin resistance via nitric oxide in malignant mesothelioma. Int J Cancer 2006; 119:17 - 27; http://dx.doi.org/10.1002/ijc.21832; PMID: 16450390
- Riganti C, Castella B, Kopecka J, Campia I, Coscia M, Pescarmona G, et al. Zoledronic acid restores doxorubicin chemosensitivity and immunogenic cell death in multidrug-resistant human cancer cells. PLoS One 2013; 8:e60975; http://dx.doi.org/10.1371/journal.pone.0060975; PMID: 23593363
- Kopecka J, Campia I, Brusa D, Doublier S, Matera L, Ghigo D, et al. Nitric oxide and P-glycoprotein modulate the phagocytosis of colon cancer cells. J Cell Mol Med 2011; 15:1492 - 504; http://dx.doi.org/10.1111/j.1582-4934.2010.01137.x; PMID: 20716130
- Zitvogel L, Kepp O, Kroemer G. Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat Rev Clin Oncol 2011; 8:151 - 60; http://dx.doi.org/10.1038/nrclinonc.2010.223; PMID: 21364688
- Castella B, Riganti C, Fiore F, Pantaleoni F, Canepari ME, Peola S, et al. Immune modulation by zoledronic acid in human myeloma: an advantageous cross-talk between Vγ9Vδ2 T cells, αβ CD8+ T cells, regulatory T cells, and dendritic cells. J Immunol 2011; 187:1578 - 90; http://dx.doi.org/10.4049/jimmunol.1002514; PMID: 21753152
- Bonneville M, O’Brien RL, Born WK. Gammadelta T cell effector functions: a blend of innate programming and acquired plasticity. Nat Rev Immunol 2010; 10:467 - 78; http://dx.doi.org/10.1038/nri2781; PMID: 20539306
- Castella B, Vitale C, Coscia M, Massaia M. Vγ9Vδ2 T cell-based immunotherapy in hematological malignancies: from bench to bedside. Cell Mol Life Sci 2011; 68:2419 - 32; http://dx.doi.org/10.1007/s00018-011-0704-8; PMID: 21584812
- Gruenbacher G, Gander H, Nussbaumer O, Nussbaumer W, Rahm A, Thurnher M. IL-2 costimulation enables statin-mediated activation of human NK cells, preferentially through a mechanism involving CD56+ dendritic cells. Cancer Res 2010; 70:9611 - 20; http://dx.doi.org/10.1158/0008-5472.CAN-10-1968; PMID: 20947520
- Maniar A, Zhang X, Lin W, Gastman BR, Pauza CD, Strome SE, et al. Human gammadelta T lymphocytes induce robust NK cell-mediated antitumor cytotoxicity through CD137 engagement. Blood 2010; 116:1726 - 33; http://dx.doi.org/10.1182/blood-2009-07-234211; PMID: 20519625